Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05601635 · ClinicalTrials.gov registry record · NA
ButyraGen™, Short Chain Fatty Acids and Gut Microbiome
A NA study, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT05601635 is a NA study that has completed, run by Clinical Nutrition Research Center, Illinois Institute of Technology. The registered enrollment target is 29 participants.
The verdict
NCT05601635, a NA study, has completed, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study is being conducted to demonstrate short chain fatty acid (SCFA), specifically butyrate, generation in stool, blood and urine in response to oral intake of ButyraGen™.
Interventions
- DIETARY_SUPPLEMENT ButyraGen™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-10-19 |
| Est. Completion | 2023-01-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05601635
The ClinicalTrials.gov registry entry for NCT05601635 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clinical Nutrition Research Center, Illinois Institute of Technology, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ButyraGen™ is the first listed.
NCT05601635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05601635 about?
NCT05601635 is a clinical study titled "ButyraGen™, Short Chain Fatty Acids and Gut Microbiome". This study is being conducted to demonstrate short chain fatty acid (SCFA), specifically butyrate, generation in stool, blood and urine in response to oral intake of ButyraGen™.
What is the current status of trial NCT05601635?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2022-10-19. Estimated completion is 2023-01-11.
What interventions are being tested in trial NCT05601635?
The interventions under investigation include: ButyraGen™ (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05601635?
This trial is sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.